56 citations
,
August 2020 in “American Journal of Clinical Dermatology” This study concluded that the ClinRO and PRO measures, along with their photoguides, offer clear and meaningful assessments for patients with alopecia areata concerning eyebrow, eyelash, and nail appearance, as well as eye irritation.
8 citations
,
August 2024 in “Clinical and Experimental Dermatology” This review discusses the limitations of existing clinician-reported outcome measures for alopecia areata and emphasizes the need for a composite scoring system to better assess disease severity.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” This study found that ritlecitinib improved patient-reported outcomes related to hair growth in individuals with alopecia areata, with some experiencing clinically meaningful hair regrowth, although changes in emotional symptoms and activity limitations were minimal and similar across treatment groups.
June 2026 in “Clinical and Experimental Dermatology” This review identified various outcome measure instruments for assessing androgenetic alopecia but found inconsistent application across clinical trials, underscoring the need for standardized assessment methods.
June 2026 in “British Journal of Dermatology” In this real-world study, 27% of alopecia areata patients treated with ritlecitinib achieved a target SALT score, a result consistent with clinical trial findings, highlighting the value of patient-reported outcomes in understanding treatment impact beyond traditional measures.